Tetra reports preliminary Phase I data for AD candidate BPN14770

Tetra Discovery Partners LLC (Grand Rapids, Mich.) reported preliminary data from a Phase I trial in 45 healthy elderly volunteers showing that twice-daily 10 and 20 mg oral doses of Alzheimer's disease candidate BPN14770 for 8 days improved complex attention/working memory and 24-hour delayed recall of verbal or sight and space-related tasks as measured by CogState Global Battery. There were no gastrointestinal adverse events reported. Data were presented at the Clinical Trials in Alzheimer's Disease meeting in Boston.

The primary endpoint of the double-blind, U.S. trial is safety, with a secondary endpoint of pharmacokinetics. Next half, the company plans to start a Phase II trial of BPN14770 to treat early AD...